Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:8/11/2008

- Peregrine Achieves Milestone as Third Phase II Trial in Its Bavituximab

Cancer Program Begins Patient Enrollment and Dosing -

TUSTIN, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer. The new trial is the second Phase II study evaluating bavituximab in advanced breast cancer patients, and Peregrine also is conducting a third Phase II combination therapy trial of bavituximab in non-small cell lung cancer (NSCLC) patients. The primary objective of the new breast cancer study is to assess the overall tumor response rate to the combination of bavituximab with carboplatin and paclitaxel.

"The combination of bavituximab with the chemotherapy drugs carboplatin and paclitaxel performed well in an earlier Phase I study, and we look forward to learning more about bavituximab's potential in this larger breast cancer study," said Steven W. King, president and CEO of Peregrine. "With three Phase II studies now underway, we look forward to significant clinical data being generated throughout the rest of this year."

In the trial's two-stage design, up to 15 patients with advanced breast cancer will be enrolled initially. The study will then be expanded up to a total of 46 patients if promising results are observed. Secondary objectives of the trial include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Tumor response will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. Patients
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
(Date:1/23/2015)... 2015 Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC ...  filed a Preliminary Proxy Statement, Schedule 14A, with the U.S. ... an update for shareholders detailing why a "YES" vote to ... Dear Shareholders, As we reflect upon the 2014 ...
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... TripAdvisor as the number one best large hotel for families ... world for their annual Travelers’ Choice Awards. , TripAdvisor ... website is home to millions of unbiased and honest traveler ...
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
(Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... Ellex Medical Lasers,Limited (ASX:ELX), a global leader ... ultrasound systems, today announced that it will,preview a ... American Academy of Ophthalmology (AAO), November 8-11, 2008 ... the Integre Pro sets a,new standard for multi-color ...
... call to explore a broader use of HPV (human papillomavirus) ... for HPV-caused oral cancers are reported in two studies by ... expert Maura Gillison, M.D., Ph.D., the first to identify HPV ... identified multiple sex partners as the most important risk factor ...
... 3 Psychemedics Corporation,(Nasdaq: PMD ) today announced ... 2008. The Company also announced a quarterly,dividend of $0.17 ... 3, 2008 to be paid on December 17, 2008. ... The Company,s third quarter revenue was $6.2 million, down ...
... Disease 4th Leading Cause of Death in U.S., ... COPD Awareness Month, to help raise awareness about Chronic,Obstructive ... Month, AllerAir will be making downloadable,tips available to COPD ... dedicating their November newsletter and blogs to raising awareness,about ...
... Nov. 3 /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. (TSX: ... the,Toronto Stock Exchange ("TSX") that it is reviewing the ... the TSX., The Company is being reviewed under ... days to comply with all requirements for continued,listing. If ...
... to act out than those without deployed kin , , MONDAY, ... deployed to Iraq and Afghanistan are more likely to have ... study shows. , Researchers studied 169 families with children aged ... day-care center at a Marine base. , Of those families, ...
Cached Medicine News:Health News:Ellex to Preview New Multi-Color Photocoagulation Laser at AAO 2Health News:Research indicates need for effective HPV vaccine for women and men and a simple HPV screening test 2Health News:Research indicates need for effective HPV vaccine for women and men and a simple HPV screening test 3Health News:Psychemedics Corporation Announces Third Quarter Results 2Health News:Psychemedics Corporation Announces Third Quarter Results 3Health News:Psychemedics Corporation Announces Third Quarter Results 4Health News:Psychemedics Corporation Announces Third Quarter Results 5Health News:AllerAir Dedicates November to COPD Awareness Month 2Health News:Listing Review initiated by the Toronto Stock Exchange 2Health News:Kids With Parent in War Zone Face Behavior Risks 2
... Model 6495 Bipolar Coaxial Temporary Pacing Lead ... bipolar technology based on the sensing and ... Unipolar Temporary Pacing Lead., ,The Streamline Temporary ... temporary sensing and pacing during and after ...
... of temporary sensing and pacing leads. Our ... temporary pacing leads and improved upon the ... and less traumatic to heart tissue. , ... to provide consistent temporary sensing and pacing ...
... device was designed specifically to obviate the ... The eNcloseII device can provide the surgeon ... better hemodynamics as compared to partial occlusion ... suggested that complete or partial clamping of ...
... Carpentier-Edwards Classic annuloplasty rings have ... choice for more than 30 ... restore the anatomical size and ... to help prevent recurrent dilatation. ...
Medicine Products: